Bluejay Diagnostics IncNASDAQ:BJDX
- LAST PRICE1.1200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1000/ 5
- Ask / Lots1.1700/ 18
- Open / Previous Close0.0000 / 1.1200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BJDX |
|---|---|---|
| 09:32 ET | 13191 | 1.1585 |
| 09:34 ET | 2000 | 1.1533 |
| 09:41 ET | 400 | 1.1585 |
| 09:52 ET | 300 | 1.16 |
| 09:57 ET | 2000 | 1.1501 |
| 10:06 ET | 600 | 1.15 |
| 10:08 ET | 1514 | 1.15 |
| 10:14 ET | 7516 | 1.15 |
| 10:19 ET | 1150 | 1.14 |
| 10:21 ET | 2000 | 1.1309 |
| 10:26 ET | 1500 | 1.1301 |
| 10:28 ET | 308 | 1.14 |
| 10:32 ET | 1200 | 1.148 |
| 10:33 ET | 500 | 1.1307 |
| 10:37 ET | 700 | 1.135 |
| 10:39 ET | 3430 | 1.13 |
| 11:06 ET | 4460 | 1.1301 |
| 11:15 ET | 300 | 1.13 |
| 11:20 ET | 1379 | 1.13 |
| 11:36 ET | 100 | 1.1294 |
| 11:42 ET | 230 | 1.1292 |
| 11:49 ET | 100 | 1.13 |
| 11:51 ET | 150 | 1.125 |
| 11:58 ET | 1700 | 1.1296 |
| 12:00 ET | 300 | 1.1299 |
| 12:02 ET | 151 | 1.1246 |
| 12:34 ET | 200 | 1.1256 |
| 12:38 ET | 8627 | 1.1201 |
| 01:35 ET | 100 | 1.11 |
| 01:53 ET | 244 | 1.1199 |
| 02:08 ET | 5000 | 1.129 |
| 02:15 ET | 477 | 1.1299 |
| 02:24 ET | 288 | 1.12 |
| 02:29 ET | 500 | 1.1288 |
| 02:44 ET | 1400 | 1.1128 |
| 02:47 ET | 1000 | 1.1188 |
| 03:21 ET | 300 | 1.1293 |
| 03:38 ET | 4237 | 1.1272 |
| 03:39 ET | 150 | 1.1289 |
| 03:45 ET | 100 | 1.125 |
| 03:56 ET | 2102 | 1.12 |
| 03:57 ET | 100 | 1.125 |
| 03:59 ET | 807 | 1.12 |
Jul 28, 2022
Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022, from 4:22PM ET on Thursday Jul 28, 2022 by GlobeNewswire
4:22PM ET on Thursday Jul 28, 2022 by GlobeNewswire
Jul 26, 2022
BRIEF-Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results, from 5:18PM ET on Tuesday Jul 26, 2022 by Thomson Reuters
5:18PM ET on Tuesday Jul 26, 2022 by Thomson Reuters-- Earnings Flash (BJDX) BLUEJAY DIAGNOSTICS Posts Q2 Revenue $249,040, from 4:31PM ET on Tuesday Jul 26, 2022 by MT Newswires
4:31PM ET on Tuesday Jul 26, 2022 by MT NewswiresBluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results, from 4:30PM ET on Tuesday Jul 26, 2022 by GlobeNewswire
4:30PM ET on Tuesday Jul 26, 2022 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bluejay Diagnostics Inc | 22.6M | -2.8x | --- |
PetVivo Holdings Inc | 21.5M | -3.9x | --- |
RenovoRx Inc | 23.8M | -2.6x | --- |
REMSleep Holdings Inc | 25.8M | -2.9x | --- |
Wearable Health Solutions Inc | 25.2M | 0.0x | --- |
Femasys Inc | 24.7M | -2.9x | --- |
Company Information
Bluejay Diagnostics, Inc. is engaged in the developing medical diagnostics tests devices. The Company offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. Symphony platform is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. The Company is developing a pipeline of diagnostic tests for Symphony, including triage of myocardial infarction (MI), congestive heart failure (CHF), neutropenic sepsis in cancer, and other disease diagnostic indications using the same Symphony platform. The Company's Symphony IL-6 product candidate is for early and rapid identification of sepsis during Emergency Department (ED), critical care triage, and neutropenic sepsis in oncology patients. Symphony IL-6 product candidate is also for monitoring disease progression during such treatment regimen.
Contact Information
- Headquarters
- 360 Massachusetts Avenue, Suite 203ACTON, MA, United States 01720
- Phone
- 978-631-0152
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $22.6M |
|---|---|
Revenue (TTM) | $249.0K |
Shares Outstanding | 20.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.41 |
Book Value | $1.01 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 90.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,561.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
